Silexion Therapeutics Corp(SLXN)Stock Analysis

SLXN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Silexion Therapeutics Corp (SLXN), a Healthcare sector company. SLXN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Silexion Therapeutics Corp reports net income of $-2.7M, free cash flow of $-3.6M. Top institutional holders of SLXN by reported 13-F value include CITADEL ADVISORS, DeepCurrents Investment Group, Polar Asset Management Partners, based on the most recent SEC filings. SLXN trades on the Nasdaq exchange and files with the SEC under CIK 2022416. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SLXN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Silexion Therapeutics Corp directly from SEC EDGAR.